Recombinant growth hormone therapy for prepubertal children with idiopathic short stature in Korea: a phase III randomized trial.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Several studies have evaluated the effects of growth hormone (GH) on auxological and biochemical parameters in children with non-GH-deficient, idiopathic short stature (ISS).

Who Took Part

The abstract describes 70 subjects taking part.

PubMed indexes the participants as young children and children, both men and women.

This was a 1-year, open-label, multicenter, phase III randomized trial of Growtropin®-II in Korean patients with ISS.

In total, 70 prepubertal subjects (39 males, 31 females) between 4 and 12 years of age were included in the study.

How the Study Was Run

In design terms this was a randomized, open-label and multicenter study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the subjects and staff both knew the treatment.

More than one site took part, so the subjects came from several places.

All patients were naive to GH treatment.

What Was Measured

The subject headings attached to it are Body Height, Case-Control Studies, Dwarfism, Growth Disorders, Growth Hormone, Human Growth Hormone and Puberty.

Author keywords: Clinical trial and Idiopathic short stature.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 70 subjects.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Journal of endocrinological investigation), a journal based in Italy.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.